Navigation Links
NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG)

SAN CARLOS, Calif., June 07, 2007 /PRNewswire-FirstCall/ -- NeurogesX, Inc. announced today the presentation of clinical data from a positive Phase 3 trial in postherpetic neuralgia (PHN). Misha-Miroslav Backonja, M.D., Professor of Neurology at University of Wisconsin in Madison and lead academic investigator in the NeurogesX trial, plans to present the results of the study in a June 8 poster session at the Second International Congress on Neuropathic Pain in Berlin, Germany. Dr. Backonja's poster presentation is based on an abstract titled, "Localized Treatment with NGX- 4010 Significantly Reduced Pain for up to 12 Weeks: Results of A Randomized, Double-Blind, 12-Week Controlled Study in Postherpetic Neuralgia Patients."

The study evaluated the effect of a single application of NGX-4010, the Company's novel dermal patch, on pain due to PHN. The primary endpoint in this Phase 3 trial was achieved, demonstrating a statistically significant reduction in pain over an 8-week period (NGX-4010, -29.6% vs. control, -19.9%; p = 0.001). The reduction of pain was sustained over 12 weeks (NGX-4010, -29.9% vs. control, -20.4%; p=0.0016).

"The results of this pivotal Phase 3 trial demonstrate NGX-4010 is effective both alone and in combination with other neuropathic pain medications for the treatment of PHN," said Dr. Backonja. "We believe that NGX-4010's unique profile has the potential to provide a meaningful therapeutic alternative to traditional therapies that need to be taken daily, most of which have systemic side effects."

According to the Centers for Disease Control, there are approximately 1.0 million cases of shingles in the United States each year, and approximate one in five shingles sufferers go on to develop PHN. People with PHN experience pain and increased sensitivity of the skin that can persist for many years.

NeurogesX plans to complete a confirmatory Phase 3 trial in PHN in t he second half of 2007 and expects to submit marketing applications to the European Medicines Agency in 2007 for European Union approval and to the U.S. Food and Drug Administration (FDA) in 2008.

About NGX-4010

NGX-4010 is a physician-administered dermal patch containing a TRPV1 agonist which targets small nerve fibers in the skin at the site of neuropathic pain. Clinical studies to date indicate that a single 30 or 60 minute administration of NGX-4010 may result in clinically meaningful pain relief for up to 12 weeks. NGX-4010 is designed to work locally in the skin without significant absorption into the bloodstream, possibly allowing users to avoid the side effects of current treatment options, such as anti- convulsants, anti-depressants and opioids.

About NeurogesX

NeurogesX is a biopharmaceutical company focused on developing novel pain management therapies. The Company's initial focus is on chronic peripheral neuropathic pain, including PHN, painful HIV-distal sensory polyneuropathy (HIV-DSP), and diabetic neuropathy. NeurogesX's late stage product portfolio is led by product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions that offers significant advantages over other pain therapies. Two Phase 3 trials with NGX-4010 have been completed and have met their primary endpoints, one in PHN and one in HIV-DSP. NGX-4010 has been granted Orphan Drug and Fast Track Status for HIV-DSP by the FDA.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to the filing for regulatory approvals and the ti ming of such filings; the successful completion of clinical trials with respect to NeurogesX' lead product candidate, NGX-4010; and market acceptance of NGX- 4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, patient enrollment for clinical trials may be difficult; past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

    NeurogesX

    Stephen Ghiglieri

    (650) 508-2116


    The Ruth Group

    Investors / Media

    Stephanie Carrington / Janine McCargo

    (646) 536-7017 / 7033

    

    

scarrington@theruthgroup.com jmccargo@theruthgroup.com

CONTACT: Stephen Ghiglieri of NeurogesX, +1-650-508-2116; or Investors,Stephanie Carrington, +1-646-536-7017, , orMedia, Janine McCargo, +1-646-536-7033, , both ofThe Ruth Group scarrington@theruthgroup.com jmccargo@theruthgroup.com

Ticker Symbol: (NASDAQ-NMS:NGSX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... today its affiliation with Tennessee Counseling Association. This new relationship allows ... the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
Breaking Medicine News(10 mins):